Ally Bridge Group leads USD65m investment in Pulmonx.

Global Banking News-May 10, 2019-Ally Bridge Group leads USD65m investment in Pulmonx

(C)2019 ENPublishing - http://www.enpublishing.co.uk

Life science investment company Ally Bridge Group said on Thursday that it has supported and led an over-subscribed USD65m financing of Pulmonx Corporation.

Based in Redwood City, California, and Neuchatel, Switzerland, Pulmonx Corporation is a provider of diagnostic and therapeutic pulmonary device technologies, with its key product approved and marketed in the US, Europe, Australia, and Asia, including China.

Pulmonx's key product, Zephyr Valve, is the first minimally-invasive device approved by the US FDA for treating patients with severe emphysema, a progressive and life-threatening form of COPD. The Zephyr Valve treatment is included in emphysema...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT